Our findings suggest that the NAFLD liver may have lower selenium levels than a disease-free liver, and further studies targeting TXNRD3 and SCLY along with enzymes involved in the transsulphuration pathway (particularly MTHFR and CBS) may elucidate the pathophysiological role of selenium metabolism in NAFLD. Here, SCLY is linked to metabolic dysfunction-associated steatotic liver disease.